NEW YORK (GenomeWeb) – Atlanta-based Cocrystal Pharma today announced licensing agreements with Duke University and Emory University for CRISPR/Cas9 technologies to be used in developing and commercializing antiviral therapeutics for hepatitis B virus (HBV) and human papilloma virus (HPV).

"We are excited to explore the CRISPR/Cas technologies to potentially develop the first virus-targeted genome-modifying treatment that may be able to provide a cure for HPV and HBV," Cocrystal CEO Jeffrey Meckler said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Sponsored by

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.